PT2475368E - N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oxi)fenil)-4-(4- metil-2-tienil)-1-ftalazinamina para utilização no tratamento de cancro resistente aos agentes antimitóticos - Google Patents

N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oxi)fenil)-4-(4- metil-2-tienil)-1-ftalazinamina para utilização no tratamento de cancro resistente aos agentes antimitóticos Download PDF

Info

Publication number: PT2475368E
Authority: PT; Portugal
Prior art keywords: phthalazinamine; pyrimidinyl; pyridin; thienyl; oxy
Prior art date: 2009-09-11

Application number

PT107550444T

Other languages

English (en)

Inventor

Marc Payton

Richard Kendall

Original Assignee

Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-09-11

Filing date

2010-09-09

Publication date

2015-02-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43216900&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2475368(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-09-09 Application filed by Amgen Inc filed Critical Amgen Inc

2015-02-10 Publication of PT2475368E publication Critical patent/PT2475368E/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Hematology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PT107550444T 2009-09-11 2010-09-09 N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oxi)fenil)-4-(4- metil-2-tienil)-1-ftalazinamina para utilização no tratamento de cancro resistente aos agentes antimitóticos PT2475368E (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US24152709P	2009-09-11	2009-09-11

Publications (1)

Publication Number	Publication Date
PT2475368E true PT2475368E (pt)	2015-02-10

Family

ID=43216900

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT107550444T PT2475368E (pt)	2009-09-11	2010-09-09	N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oxi)fenil)-4-(4- metil-2-tienil)-1-ftalazinamina para utilização no tratamento de cancro resistente aos agentes antimitóticos

Country Status (34)

Country	Link
US (1)	US20120028917A1 (pt)
EP (2)	EP2475368B1 (pt)
JP (1)	JP5851403B2 (pt)
KR (1)	KR20120082896A (pt)
CN (1)	CN102869361A (pt)
AU (1)	AU2010292225C1 (pt)
BR (1)	BR112012008325A2 (pt)
CA (1)	CA2773838C (pt)
CL (1)	CL2012000640A1 (pt)
CR (1)	CR20120171A (pt)
DK (1)	DK2475368T3 (pt)
EA (1)	EA020526B1 (pt)
ES (1)	ES2528485T3 (pt)
HK (1)	HK1205457A1 (pt)
HR (1)	HRP20150104T1 (pt)
HU (1)	HUE024568T2 (pt)
IL (1)	IL218569A0 (pt)
MA (1)	MA33658B1 (pt)
ME (1)	ME02048B (pt)
MX (1)	MX2012003041A (pt)
NZ (1)	NZ598758A (pt)
PE (1)	PE20120895A1 (pt)
PH (1)	PH12012500504A1 (pt)
PL (1)	PL2475368T3 (pt)
PT (1)	PT2475368E (pt)
RS (1)	RS53807B1 (pt)
SG (1)	SG179102A1 (pt)
SI (1)	SI2475368T1 (pt)
SM (1)	SMT201500028B (pt)
TN (1)	TN2012000110A1 (pt)
TW (1)	TW201121956A (pt)
UA (1)	UA107675C2 (pt)
WO (1)	WO2011031842A1 (pt)
ZA (1)	ZA201202472B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8921367B2 (en)	2012-05-31	2014-12-30	Amgen Inc.	Use of AMG 900 for the treatment of cancer
CN103664737A (zh) *	2012-09-25	2014-03-26	杨子娇	一类治疗房角狭窄的化合物及其用途
US9963701B2 (en)	2013-09-30	2018-05-08	Korea Institute Of Radiological & Medical Sciences	Pharmaceutical composition for treatment of radiation- or drug-resistant cancer comprising HRP-3 inhibitor
SI3068393T1 (sl)	2013-11-11	2022-11-30	Amgen Inc.	Kombinirana terapija, ki vključuje zaviralec MDM2 in eno ali več dodatnih farmacevtskih učinkovin za zdravljenje različnih vrst raka
AU2014357545B2 (en) *	2013-12-03	2018-10-25	Amgen Inc.	Crystalline forms of N-(4-((3-(2-amino-4-pyrimidinyl) - 2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1 -phthalazinamine pharmaceutically acceptable salts and uses thereof
CA2940237C (en) *	2014-02-21	2023-03-07	Frost Biologic, Inc.	Antimitotic amides for the treatment of cancer and proliferative disorders
AU2017248807A1 (en) *	2016-04-15	2018-10-25	Felicitex Therapeutics, Inc.	Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis
JOP20190272A1 (ar)	2017-05-22	2019-11-21	Amgen Inc	مثبطات kras g12c وطرق لاستخدامها
EP4403175A3 (en)	2017-09-08	2024-10-02	Amgen Inc.	Inhibitors of kras g12c and methods of using the same
CA3098574A1 (en)	2018-05-04	2019-11-07	Amgen Inc.	Kras g12c inhibitors and methods of using the same
AU2019336588B2 (en)	2018-06-12	2022-07-28	Amgen Inc.	KRAS G12C inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer
JP7377679B2 (ja)	2018-11-19	2023-11-10	アムジエン・インコーポレーテツド	がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
NZ782284A (en)	2019-05-21	2024-11-29	Amgen Inc	Solid state forms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20060178318A1 (en) *	2003-07-03	2006-08-10	Shubha Anand	Use of aurora kinase inhibitors for reducing the resistance of cancer cells
UA93538C2 (en) *	2006-01-23	2011-02-25	Амген Инк.	Aurora kinase modulators and method of use
CA2637658C (en)	2006-01-23	2012-07-17	Amgen Inc.	Aurora kinase modulators and method of use
US7560551B2 (en) *	2006-01-23	2009-07-14	Amgen Inc.	Aurora kinase modulators and method of use
GB0609619D0 (en) *	2006-05-16	2006-06-21	Astrazeneca Ab	Combination
GB0609621D0 (en) *	2006-05-16	2006-06-21	Astrazeneca Ab	Novel co-crystal

2010
- 2010-09-09 SI SI201030865T patent/SI2475368T1/sl unknown
- 2010-09-09 RS RS20150065A patent/RS53807B1/sr unknown
- 2010-09-09 ES ES10755044.4T patent/ES2528485T3/es active Active
- 2010-09-09 HR HRP20150104AT patent/HRP20150104T1/hr unknown
- 2010-09-09 WO PCT/US2010/048247 patent/WO2011031842A1/en not_active Ceased
- 2010-09-09 MX MX2012003041A patent/MX2012003041A/es active IP Right Grant
- 2010-09-09 US US12/878,539 patent/US20120028917A1/en not_active Abandoned
- 2010-09-09 EP EP10755044.4A patent/EP2475368B1/en active Active
- 2010-09-09 DK DK10755044T patent/DK2475368T3/en active
- 2010-09-09 CN CN2010800512813A patent/CN102869361A/zh active Pending
- 2010-09-09 EP EP14186203.7A patent/EP2818170B1/en active Active
- 2010-09-09 HU HUE10755044A patent/HUE024568T2/hu unknown
- 2010-09-09 PL PL10755044T patent/PL2475368T3/pl unknown
- 2010-09-09 NZ NZ598758A patent/NZ598758A/en not_active IP Right Cessation
- 2010-09-09 EA EA201270383A patent/EA020526B1/ru not_active IP Right Cessation
- 2010-09-09 JP JP2012528891A patent/JP5851403B2/ja active Active
- 2010-09-09 BR BR112012008325A patent/BR112012008325A2/pt not_active IP Right Cessation
- 2010-09-09 PE PE2012000323A patent/PE20120895A1/es not_active Application Discontinuation
- 2010-09-09 SG SG2012017422A patent/SG179102A1/en unknown
- 2010-09-09 KR KR1020127009226A patent/KR20120082896A/ko not_active Ceased
- 2010-09-09 CA CA2773838A patent/CA2773838C/en active Active
- 2010-09-09 UA UAA201204585A patent/UA107675C2/ru unknown
- 2010-09-09 AU AU2010292225A patent/AU2010292225C1/en active Active
- 2010-09-09 ME MEP-2015-10A patent/ME02048B/me unknown
- 2010-09-09 PT PT107550444T patent/PT2475368E/pt unknown
- 2010-09-09 PH PH1/2012/500504A patent/PH12012500504A1/en unknown
- 2010-09-10 TW TW099130742A patent/TW201121956A/zh unknown
2012
- 2012-03-11 IL IL218569A patent/IL218569A0/en unknown
- 2012-03-12 TN TNP2012000110A patent/TN2012000110A1/en unknown
- 2012-03-12 CL CL2012000640A patent/CL2012000640A1/es unknown
- 2012-04-04 ZA ZA2012/02472A patent/ZA201202472B/en unknown
- 2012-04-04 MA MA34753A patent/MA33658B1/fr unknown
- 2012-04-10 CR CR20120171A patent/CR20120171A/es unknown
2013
- 2013-01-16 HK HK15106028.6A patent/HK1205457A1/en unknown
2015
- 2015-02-09 SM SM201500028T patent/SMT201500028B/xx unknown

Also Published As

Publication number	Publication date
EA020526B1 (ru)	2014-11-28
IL218569A0 (en)	2012-05-31
EA201270383A1 (ru)	2013-04-30
CR20120171A (es)	2012-08-09
UA107675C2 (xx)	2015-02-10
ES2528485T3 (es)	2015-02-10
NZ598758A (en)	2013-12-20
EP2818170B1 (en)	2018-12-05
HRP20150104T1 (xx)	2015-03-13
HK1173655A1 (en)	2013-05-24
CL2012000640A1 (es)	2012-09-21
CA2773838C (en)	2016-05-31
MA33658B1 (fr)	2012-10-01
KR20120082896A (ko)	2012-07-24
US20120028917A1 (en)	2012-02-02
JP5851403B2 (ja)	2016-02-03
AU2010292225B2 (en)	2012-12-13
BR112012008325A2 (pt)	2017-08-29
TN2012000110A1 (en)	2013-09-19
CN102869361A (zh)	2013-01-09
TW201121956A (en)	2011-07-01
AU2010292225A1 (en)	2012-04-12
CA2773838A1 (en)	2011-03-17
ME02048B (me)	2015-05-20
WO2011031842A1 (en)	2011-03-17
HUE024568T2 (hu)	2016-02-29
DK2475368T3 (en)	2015-03-09
HK1205457A1 (en)	2015-12-18
EP2475368A1 (en)	2012-07-18
RS53807B1 (sr)	2015-06-30
EP2818170A1 (en)	2014-12-31
JP2013504582A (ja)	2013-02-07
AU2010292225C1 (en)	2013-06-27
PH12012500504A1 (en)	2015-04-29
PL2475368T3 (pl)	2015-05-29
SG179102A1 (en)	2012-04-27
SMT201500028B (it)	2015-03-05
ZA201202472B (en)	2012-12-27
PE20120895A1 (es)	2012-08-19
MX2012003041A (es)	2012-06-27
SI2475368T1 (sl)	2015-03-31
EP2475368B1 (en)	2014-12-17

Publication	Publication Date	Title
PT2475368E (pt)	2015-02-10	N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oxi)fenil)-4-(4- metil-2-tienil)-1-ftalazinamina para utilização no tratamento de cancro resistente aos agentes antimitóticos
IL213068A0 (en)	2011-07-31	Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
IL248204A0 (en)	2016-11-30	Combined treatment of tumors expressing 38cd
SI2343070T1 (sl)	2015-01-30	Zdravljenje s pirfenidonom za bolnike z atipiäśno jetrno funkcijo
ZA200807234B (en)	2009-09-30	GSK-3 inhibitors for the treatment of osteoporosis
ZA200906126B (en)	2010-06-30	Use of IL-23 antigonists for treatment of infection
ZA200900734B (en)	2010-04-28	Combination treatment for metabolic disorders
MX315904B (es)	2013-11-29	Inhibidores de fosfoinosituro-3 cinasa.
ZA200905639B (en)	2010-06-30	Re-characterization of bets at table games
IL196517A0 (en)	2009-11-18	Jak inhibitors for treatment of myeloproliferative disorders
PT2954932T (pt)	2018-12-12	Utilização terapêutica de diaminofenotiazinas
EP2049139A4 (en)	2009-06-24	TREATMENT OF TUMORS EXPRESSING RAS
EP2205236A4 (en)	2012-08-22	NEW MEANS FOR THE TREATMENT OF DISEASES AND FUNCTIONAL DISORDERS
IL194189A0 (en)	2009-08-03	Combination treatment of metabolic disorders
SI2632921T1 (sl)	2019-01-31	Polimorfi in soli 6-(1H- indol-4-il)-4-(5-((4-(1-metiletil)-1-piperazinil)metil)-1,3-oksazol-2- il)-1H-indazola kot inhibitorji PI3K za uporabo pri zdravljenju npr. respiratornih motenj
IL205137A0 (en)	2010-11-30	5-cyanothienopyridines for the treatment of tumours
IL238394B (en)	2018-05-31	Preparations containing a combination of factors for the treatment of cancer
PL3002009T3 (pl)	2021-12-13	Leczenie przewlekłej białaczki szpikowej opornej na imatynib z mutacją 1457T>C w genie bcrabl, wykorzystujące bosutynib
EP2213303A4 (en)	2011-12-28	PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CATARACT
ZA201000225B (en)	2011-03-30	Treatment of depression
ZA200901452B (en)	2010-04-28	Treatment of vertigo with acetyl-L-leucine
SI2331098T1 (sl)	2018-10-30	Postopki za dajanje iloperidona
SI2129377T1 (sl)	2012-01-31	Tekoäśa formulacija soli 4-(2-(4-metilfenilsulfanil)fenil)piperidina
IL194066A0 (en)	2009-09-22	Therapeutic composition for treatment of tinnitus
IL212302A0 (en)	2011-06-30	(pyrrolidin-2 -yl) phenyl derivatives for use in the treatment of pain